Durvalumab Plus Tremelimumab Elicits Favorable PFS Rates in Advanced Sarcomas
August 23rd 2022The combination of durvalumab and tremelimumab demonstrated positive progression-free survival and overall survival rates with expected toxicity data in patients with advanced or metastatic soft tissue and bone sarcomas.
Read More
Perioperative Immunotherapy Demonstrates Promising pCR Rates in dMMR/MSI-H Gastric and GEJ Cancer
August 22nd 2022Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited positive pathologic complete response rates in patients with locally advanced resectable mismatch repair–deficient and/or microsatellite instability–high gastric or gastroesophageal junction adenocarcinoma.
Read More
Concurrent Galunisertib and Neoadjuvant Chemoradiotherapy Improves CR Rates in Rectal Cancer
August 19th 2022The addition of galunisertib to neoadjuvant chemoradiotherapy improved complete response rates in patients with locally advanced rectal cancer, according to findings from a phase 2 study.
Read More
Elotuzumab plus pomalidomide and dexamethasone demonstrated a significant improvement in overall survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma who previously received treatment with lenalidomide and a proteasome inhibitor.
Read More
Immunotherapy Combinations Launch Into Earlier Lines and Signal Success in Metastatic Solid Tumors
August 17th 2022Successful, established immunotherapies that have been approved for use in the metastatic setting are rapidly moving forward into the adjuvant and neoadjuvant settings, and novel agents are emerging in later lines.
Read More
Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL
August 17th 2022Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.
Read More
Teclistamab Demonstrates Durable Response Rates in BCMA-Pretreated Multiple Myeloma
August 15th 2022Saad Z. Usmani, MD, MBA, FACP, discusses key efficacy findings that support the use of teclistamab in patients with relapsed/refractory multiple myeloma who have had prior exposure to BCMA-targeted agents.
Read More
Adagrasib Elicits Responses in KRAS G12C–Mutant NSCLC
August 12th 2022Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.
Read More
Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC
August 6th 2022Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.
Read More
Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.
Read More
Molecular Testing Continues to Predict Treatment Efficacy in Ovarian Cancer
July 22nd 2022Bradley J. Monk, MD, FACS, FACOG, discusses the importance of helping patients make informed decisions about their care options and the future role of antibody-drug conjugate targets in the biomarker testing arena.
Read More
Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL
July 20th 2022Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.
Read More
BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma
July 19th 2022Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.
Read More
Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer
July 15th 2022Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.
Read More
Seribantumab Demonstrates Positive Response Rates, Tolerability in NRG1 Fusion+ Solid Tumors
July 14th 2022Daniel R. Carrizosa, MD, MS, discusses the design and important efficacy and safety findings from CRESTONE trial evaluating seribantumab and the importance of finding a targeted therapy for patients with solid tumors harboring NRG1 fusions.
Read More
Patient Selection May be Key for Leveraging Elacestrant in ER+/HER2- Breast Cancer
July 13th 2022Francois-Clement Bidard, MD, PhD, highlights the benefits of elacestrant in chemotherapy-naïve patients and in those with ESR1 mutations, explains the results of a subgroup analysis done of the EMERALD trial in patients without prior chemotherapy, and voices his hopes for the future regarding other oral selective estrogen receptor degraders in development.
Read More
Machine Learning Increases Diagnostic Accessibility, Saves Time in Histopathology
July 13th 2022R. Lor Randall, MD, FACS, shares the successes achieved so far with machine learning in histopathology, explained the positive effect this technology can have on institutions, and advocated for further use of technology to aid treatment advances.
Read More
ADCs and TKIs Plus Immunotherapy Signal the Future of Urothelial Carcinoma and RCC
July 12th 2022Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.
Read More
Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL
July 11th 2022Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.
Read More
Predictive ctDNA Testing Opens the Door for Increasingly Personalized Care in Colon Cancer
July 7th 2022Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.
Read More
New Findings in Breast Cancer Trials Call for Restructuring of Disease Subtypes
July 6th 2022Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer
Read More
Tislelizumab Plus Chemotherapy Elicits Strong Survival Benefit in Esophageal Cancer
June 30th 2022The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma
Read More
Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL
June 29th 2022Second-line lisocabtagene maraleucel provides an earlier CAR T-cell treatment option that improves survival outcomes and produces a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma, including those who are older and have comorbidities.
Read More
Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma
June 28th 2022Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.
Read More